Tumor treating fields combined with ionizing radiation inhibit the malignant phenotype of lung cancer brain metastasis cells by suppressing DNA damage repair pathways.

Brain Stimul

Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsh

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Brain metastasis (BrM) is a common complication of advanced tumors with poor prognosis. Although radiotherapy remains a key treatment for BrM, it is plagued by issues such as radiation-induced brain necrosis, neurocognitive impairment, and progress post-treatment. Tumor Treating Fields (TTFields) therapy employs medium frequency (100∼300 kHz) and low intensity (1∼3 v/cm) alternating electric fields to inhibit tumors. We explored the effects and mechanisms of TTFields combined with ionizing radiation (IR) on the malignant phenotype of lung cancer brain metastasis (LCBM) cells, with the aim of advancing the clinical adoption of TTFields.

Methods: LCBM cells H1915, PC9-Brm and primary cells were used. The experiments included four groups: Control, 6 Gy, TTFields, and 6 Gy + TTFields group. Cell viability and the number of EDU or Ki67-positive cells, ability of migration and colony formation were assessed; Cell morphology was observed by H&E staining; Bulk transcriptome revealed the potential mechanisms, with the protein levels of differentially expressed genes (DEGs) verified through immunofluorescence assay. DNA damage repair pathways were validated by Western Blot. Additionally, ROS levels, and HO-1 expression were evaluated.

Results: The combination of 150 kHz, 2∼2.5 v/cm TTFields and 6 Gy IR effectively suppressed the viability and the number of EDU-positive and Ki67-positive LCBM cells. Following TTFields and IR, the tumor cells exhibited altered morphology and reduced clonogenic and migratory capacities. RNA-seq revealed associations between TTFields combined with IR and various biological processes and mechanisms, including redox reactions (primarily related to mitochondria), DNA replication, transition metal ion transmembrane transport, and heme metabolism. Furthermore, TTFields combined with IR enhanced γH2AX and 53BP1 levels. Increased ROS and HO-1 expression were observed post-treatment. Similarly, LCBM primary cells exhibited decreased Ki67-positive cells along with increased γH2AX and 53BP1 foci following TTFields and IR. TTFields combined with IR exhibited significant suppression on homologous recombination (HR) markers (p-ATM, RAD51), non-homologous end joining (NHEJ) components (DNA-PKcs, KU70, KU80), and microhomology-mediated end joining (MMEJ) effectors (PARP1, p95-NBS1) versus RT alone.

Conclusions: TTFields combined with IR effectively inhibits LCBM cells. Mechanistically, this combined treatment enhanced DNA damage, suppressed DNA damage repair, and elevates ROS levels.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brs.2025.07.014DOI Listing

Publication Analysis

Top Keywords

ttfields combined
20
dna damage
16
lcbm cells
16
brain metastasis
12
damage repair
12
cells
10
ttfields
10
tumor treating
8
treating fields
8
combined ionizing
8

Similar Publications

Glioma is an aggressive brain tumor that requires challenging treatments. Tumor Treating Fields (TTFields), an FDA-approved therapy for glioblastoma (GBM), pleural mesothelioma, and platinum-refractory metastatic nonsmall cell lung cancer (in combination with PD-1/PD-L1 inhibitors or docetaxel), employs specific frequency electric fields to disrupt cell division and enhance treatment efficacy. However, their molecular mechanisms remain unclear.

View Article and Find Full Text PDF

Tumor Treating Fields (TTFields) are low-intensity, intermediate-frequency alternating electric fields that exert antimitotic effects on cancer cells. This study is the first to evaluate the in vitro efficacy of TTFields on biliary tract cancer (BTC) cell lines HCCC-9810 and RBE, investigating their sensitivity to TTFields across varying frequencies and electric field intensities (100-200 kHz, 1.3-2.

View Article and Find Full Text PDF

Tumor treating fields combined with ionizing radiation inhibit the malignant phenotype of lung cancer brain metastasis cells by suppressing DNA damage repair pathways.

Brain Stimul

July 2025

Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, China; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsh

Background: Brain metastasis (BrM) is a common complication of advanced tumors with poor prognosis. Although radiotherapy remains a key treatment for BrM, it is plagued by issues such as radiation-induced brain necrosis, neurocognitive impairment, and progress post-treatment. Tumor Treating Fields (TTFields) therapy employs medium frequency (100∼300 kHz) and low intensity (1∼3 v/cm) alternating electric fields to inhibit tumors.

View Article and Find Full Text PDF

Introduction: Glioblastoma (GBM) stands as one of the most challenging malignancies to treat, with a prognosis that remains notably poor despite advancements in therapeutic strategies.

Areas Covered: TTFields therapy is a novel approach to targeting cancer cell proliferation through alternating electric fields. The mechanism of action, dielectrophoresis, selectively disrupts mitotic processes in replicating cells, offering a localized treatment option with minimal systemic side effects.

View Article and Find Full Text PDF

Glioblastomas (GBM) are aggressive tumors, which systematically relapse despite standard treatment associating surgery, chemotherapy and radiation therapy. More recently, GBM therapy now includes another therapeutic modality option, Tumor Treating Fields (TTFields) given in combination with Temozolomide (TMZ) following standard treatment. However even with the adjunction of TTFields, GBM remains a lethal disease due to treatment resistance.

View Article and Find Full Text PDF